Ip. Jensen et al., THE 1994 HUMAN PARVOVIRUS B19 EPIDEMIC IN DENMARK - DIAGNOSTIC AND EPIDEMIOLOGIC EXPERIENCE, APMIS. Acta pathologica, microbiologica et immunologica Scandinavica, 106(9), 1998, pp. 843-848
In 1994 the first human parvovirus B19 (B19) epidemic to be documented
in Denmark was recorded from February 2 to September 30. In total, 10
,333 serum samples were tested for specific B19 IgM and IgG antibodies
, using IDEIA(TM) Parvovirus B19 IgM and IgG kits. The prevalence of B
19 IgM positivity was 11% for the whole period and 29% at the peak of
the epidemic in week 14, declining from week 39 and onwards to 1-3%. T
he prevalence of B19 IgG (IgM-negative samples) was 60%, indicating an
earlier infection, and the same for men and women. The gender distrib
ution of tested patients was the same at the beginning of the epidemic
as at the end of the epidemic and a year after its peak, i.e. 86% of
samples were from women and only 14% from men. Age distribution for wo
men was the same for the three periods (median age 34 years). For men
the median age was 32 years, 39 years and 31 years, respectively. Only
a few samples from children were tested. No change in test pattern wa
s observed during the three periods. Approximately 75% of all samples
tested were from women of childbearing age (18-45 years old), suggesti
ng a fear of fetal complications in an actual or future pregnancy, rat
her than a serological verification of clinical symptoms. From the spa
rse clinical information that accompanied the serum sample we were not
able to demonstrate that women were more likely than men to have a sy
mptomatic B19 infection. With reservations we estimate that 14% of adv
erse pregnancy outcome is correlated with a B19 infection.